All Stories

  1. Prevalence of Sars-Cov-2 Infection in Health Workers (HWs) and Diagnostic Test Performance: The Experience of a Teaching Hospital in Central Italy
  2. Occurrence of exocrine pancreatic insufficiency in patients with advanced neuroendocrine tumors treated with somatostatin analogs
  3. SARS-CoV2 RNA detection in a pancreatic pseudocyst sample
  4. The Trends of Complicated Acute Colonic Diverticulitis—A Systematic Review of the National Administrative Databases
  5. Cell Blood Count Alterations and Patterns of Anaemia in Autoimmune Atrophic Gastritis at Diagnosis: A Multicentre Study
  6. Chronic atrophic gastritis: Natural history, diagnosis and therapeutic management. A position paper by the Italian Society of Hospital Gastroenterologists and Digestive Endoscopists [AIGO], the Italian Society of Digestive Endoscopy [SIED], the Italian...
  7. Occurrence of Acute Oesophageal Necrosis (Black Oesophagus) in a Single Tertiary Centre
  8. Role of Combined [68Ga]Ga-DOTA-SST Analogues and [18F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review
  9. Do Alterations in Bone Mineral Density Go Beyond Borders in Adults With Celiac Disease?
  10. Multidisciplinary Management of Neuroendocrine Neoplasia: A Real-World Experience from a Referral Center
  11. A single vial is enough in the absence of endoscopic suspected intestinal metaplasia – less is more!
  12. Gastroesophageal reflux symptoms and microscopic esophagitis in a cohort of consecutive patients affected by atrophic body gastritis: a pilot study
  13. Treatment of diverticular disease, targeting symptoms or underlying mechanisms
  14. Risk Factors Associated with the Occurrence of Autoimmune Diseases in Adult Coeliac Patients
  15. Recent advances in understanding and managing diverticulitis
  16. Demographic and clinical features distinguish subgroups of diverticular disease patients: Results from an Italian nationwide registry
  17. Rifaximin and diverticular disease: Position paper of the Italian Society of Gastroenterology (SIGE)
  18. Cost of detecting gastric neoplasia by surveillance endoscopy in atrophic gastritis in Italy: A low risk country
  19. Role of Fiber in Symptomatic Uncomplicated Diverticular Disease: A Systematic Review
  20. Luminescent Immunoprecipitation System (LIPS) for Detection of Autoantibodies Against ATP4A and ATP4B Subunits of Gastric Proton Pump H+,K+-ATPase in Atrophic Body Gastritis Patients
  21. Upper gastrointestinal symptoms in autoimmune gastritis
  22. Time trend occurrence of duodenal intraepithelial lymphocytosis and celiac disease in an open access endoscopic population
  23. Role of endoscopic surveillance for intestinal metaplasia limited to the antrum
  24. Italian Guidelines
  25. Eosinophilic gastroenteritis in a woman with multiple sclerosis on dimethyl fumarate
  26. Gastric precancerous conditions andHelicobacter pyloriinfection in dyspeptic patients with or without endoscopic lesions
  27. A multicenter prospective study of the real-time use of narrow-band imaging in the diagnosis of premalignant gastric conditions and lesions
  28. Letter: gastric cancer and pernicious anaemia - only a minority of UK pernicious anaemia patients have had a gastroscopy - authors’ reply
  29. A case of Barrett’s oesophagus in pernicious anaemia: acid is not the only culprit!
  30. Pernicious Anemia: Time to Justify Endoscopic Monitoring?
  31. Endoscopic appearances of polypoid type 1 gastric microcarcinoids by narrow-band imaging
  32. Probiotics and Diverticular Disease
  33. Symbiotics, Probiotics, and Fiber Diet in Diverticular Disease
  34. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015
  35. ATPase4A Autoreactivity and Its Association With Autoimmune Phenotypes in the Type 1 Diabetes Genetics Consortium Study
  36. Practice parameters for the treatment of colonic diverticular disease: Italian Society of Colon and Rectal Surgery (SICCR) guidelines
  37. Prevalence and distribution of colonic diverticula assessed with CT colonography (CTC)
  38. Single nucleotide polymorphisms related to vitamin B12 serum levels in autoimmune gastritis patients with or without pernicious anaemia
  39. Occurrence of gastric cancer and carcinoids in atrophic gastritis during prospective long-term follow up
  40. E-cadherin germline mutation carriers: clinical management and genetic implications
  41. Updated features associated with type 1 gastric carcinoids patients: a single-center study
  42. Editorial: mucosal healing and adherence to the gluten-free diet in coeliac disease - authors' reply
  43. Prevalence of lesions detected at upper endoscopy: An Italian survey
  44. Detection of Gastric Precancerous Conditions in Daily Clinical Practice: A Nationwide Survey
  45. Thyro-gastric autoimmunity in patients with differentiated thyroid cancer: a prospective study
  46. Italian consensus conference for colonic diverticulosis and diverticular disease
  47. Histological recovery and gluten-free diet adherence: a prospective 1-year follow-up study of adult patients with coeliac disease
  48. Gastric cancer in patients with type I gastric carcinoids
  49. Are clinical features able to predict Helicobacter pylori gastritis patterns? Evidence from tertiary centers
  50. Proton pump inhibitor therapy and potential long-term harm
  51. Gastric carcinoid in the absence of atrophic body gastritis and with low Ki67 index: a clinical challenge
  52. Helicobacter pyloriinfection and drugs malabsorption
  53. Symptom patterns can distinguish diverticular disease from irritable bowel syndrome
  54. A survey of pharmacological and nonpharmacological treatment of functional gastrointestinal disorders
  55. Letter: gastric cancer and pernicious anaemia - oftenHelicobacter pyloriin disguise; authors' reply
  56. Intestinal metaplasia surveillance: Searching for the road-map
  57. Systematic review: gastric cancer incidence in pernicious anaemia
  58. No higher risk for colorectal cancer in atrophic gastritis-related hypergastrinemia
  59. Appropriateness of the Indication for Colonoscopy
  60. Chronic Idiophatic Urticaria and Helicobacter Pylori: A Specific Pattern of Gastritis and Urticaria Remission after Helicobacter Pylori Eradication
  61. Clinical features of symptomatic uncomplicated diverticular disease: a multicenter Italian survey
  62. Micronutrients (Other than iron) and Helicobacter pylori Infection: A Systematic Review
  63. High-fibre diet andLactobacillus paracasei B21060in symptomatic uncomplicated diverticular disease
  64. Is proliferative colonic disease presentation changing?
  65. Risk for gastric neoplasias in patients with chronic atrophic gastritis: A critical reappraisal
  66. Type I Gastric Carcinoids: A Prospective Study on Endoscopic Management and Recurrence Rate
  67. Role of gastritis pattern on Helicobacter pylori eradication
  68. Treatment of Diverticular Disease of the Colon and Prevention of Acute Diverticulitis: A Systematic Review
  69. Diagnosis and Management of Pernicious Anemia
  70. Development of type I gastric carcinoid in patients with chronic atrophic gastritis
  71. Reversal of atrophic body gastritis after H. pylori eradication at long-term follow-up
  72. Immunoproteomics of Helicobacter pylori infection in patients with atrophic body gastritis, a predisposing condition for gastric cancer
  73. HLA-DRB1*03 and DRB1*04 are associated with atrophic gastritis in an Italian population
  74. Low prevalence of idiopathic peptic ulcer disease: An Italian endoscopic survey
  75. Cost-effectiveness of Endoscopic Surveillance for Gastric Intestinal Metaplasia
  76. Helicobacter pyloriimmunoproteomics in gastric cancer and gastritis of the carcinoma phenotype
  77. Appropriateness of the indication for upper endoscopy: A meta-analysis
  78. Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis
  79. Systematic review: distribution of advanced neoplasia according to polyp size at screening colonoscopy
  80. High efficacy of bismuth subcitrate for Helicobacter pylori eradication in pangastritis
  81. Reassessment of Intrinsic Factor and Parietal Cell Autoantibodies in Atrophic Gastritis With Respect to Cobalamin Deficiency
  82. Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy
  83. Systematic review:Heliocobacter pyloriinfection and impaired drug absorption
  84. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers
  85. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biotherapy
  86. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Chemotherapy in Patients with Neuroendocrine Tumors
  87. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors:Echocardiography
  88. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Follow-Up and Documentation
  89. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs
  90. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors
  91. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological Examinations
  92. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Somatostatin Receptor Imaging with 111In-Pentetreotide
  93. Pernicious anemia: New insights from a gastroenterological point of view
  94. Pre-endoscopic screening for Helicobacter pylori and celiac disease in young anemic women
  95. Benefit of concomitant gastrointestinal and gynaecological evaluation in premenopausal women with iron deficiency anaemia
  96. A Prospective Study of Gastric Carcinoids and Enterochromaffin-Like Cell Changes in Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome: Identification of Risk Factors
  97. The Eradication of Helicobacter pylori is Affected by Body Mass Index (BMI)
  98. Occurrence and Risk Factors for Autoimmune Thyroid Disease in Patients with Atrophic Body Gastritis
  99. Artificial neural networks in the recognition of the presence of thyroid disease in patients with atrophic body gastritis
  100. Assessing the severity of atrophic gastritis
  101. Is interleukin-1 genotyping useful for the clinical management of patients with atrophic body gastritis?
  102. After Helicobacter pylori, Genetic Susceptibility to Gastric Carcinoma Revisited
  103. Three months of octreotide treatment decreases gastric acid secretion and argyrophil cell density in patients with Zollinger-Ellison syndrome and antral G-cell hyperfunction
  104. Zollinger-Ellison syndrome and antral G-cell hyperfunction in patients with resistant duodenal ulcer disease
  105. Efficacy of long-term therapy with low doses of omeprazole in the control of gastric acid secretion in Zollinger-Ellison syndrome patients
  106. Omeprazole versus famotidine in the short-term treatment of duodenal ulcer disease
  107. CagA and VacA are Immunoblot Markers of Past Helicobacter pylori Infection in Atrophic Body Gastritis
  108. Corpus-predominant gastritis as a risk factor for false-negative13C-urea breath test results
  109. Thyroxine in Goiter, H. pylori Infection, and Gastritis
  110. Thyroxine in Goiter,Helicobacter pyloriInfection, and Chronic Gastritis
  111. Unawareness of gastrointestinal symptomatology in adult coeliac patients with unexplained iron-deficiency anaemia presentation
  112. Western Blotting of Total Lysate of Helicobacter pylori in Cases of Atrophic Body Gastritis
  113. Long-term follow-up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection
  114. Of Bacteria, Acid, and Blood
  115. Occurrence and risk factors for benign epithelial gastric polyps in atrophic body gastritis on diagnosis and follow-up
  116. Early Manifestations of Gastric Autoimmunity in Patients with Juvenile Autoimmune Thyroid Diseases
  117. Role of Noninvasive Tests (13C-Urea Breath Test and Stool Antigen Test) as Additional Tools in Diagnosis ofHelicobacter PyloriInfection in Patients with Atrophic Body Gastritis
  118. Can patient characteristics predict the outcome of endoscopic evaluation of iron deficiency anemia: a multiple logistic regression analysis
  119. Large hiatal hernia in patients with iron deficiency anaemia: a prospective study on prevalence and treatment
  120. Gastric Neuroendocrine Tumors
  121. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors
  122. Symptom-based approach to colorectal cancer: survey of primary care physicians in Italy
  123. IS ENDOSCOPY WORTHWHILE IN MENSTRUATING FEMALES WITH IRON DEFICIENCY?
  124. Role of small bowel investigation in iron deficiency anaemia after negative endoscopic/histologic evaluation of the upper and lower gastrointestinal tract
  125. DXA vs. QCT for subclinical celiac disease patients
  126. Intragastric Ascorbic But Not Uric Acid is Depleted in Relation with the Increased pH in Patients with Atrophic Body Gastritis and H. Pylori Gastritis
  127. Co-existence of hyperparathyroidism, hypergastrinaemia and multiple gastric carcinoids is not always due to incomplete expression of the MEN-1 syndrome
  128. Concomitant alterations in intragastric pH and ascorbic acid concentration in patients with Helicobacter pylori gastritis and associated iron deficiency anaemia
  129. The stomach and iron deficiency anaemia: a forgotten link
  130. Antibiotic Prophylaxis of Bacterial Infections in Cirrhotic Inpatients: a Meta-Analysis of Randomized Controlled Trials
  131. Timing and sampling in surveillance of premalignant gastric lesions
  132. The long-term effects of cure of Helicobacter pylori infection on patients with atrophic body gastritis
  133. Consequences of Helicobacter pylori infection on the absorption of micronutrients
  134. Effect of chronic hypergastrinemia on human enterochromaffin-like cells: Insights from patients with sporadic gastrinomas
  135. Progression of gastric enterochromaffin-like cells growth in Zollinger-Ellison syndrome and atrophic body gastritis patients
  136. Role of Helicobacter pylori serology in atrophic body gastritis after eradication treatment
  137. Iron Deficiency Anaemia Caused by Nonspecific (Idiopathic) Small Bowel Ulceration: An Uncommon Presentation of an Uncommon Disease
  138. Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid
  139. Involvement of the corporal mucosa and related changes in gastric acid secretion characterize patients with iron deficiency anaemia associated with Helicobacter pylori infection
  140. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome?
  141. Gastrointestinal causes of refractory iron deficiency anemia in patients without gastrointestinal symptoms
  142. Two-thirds of Atrophic Body Gastritis Patients Have Evidence of Helicobacter pylori Infection
  143. Occurrence and relapse of bleeding from duodenal ulcer: respective roles of acid secretion and Helicobacter pylori infection
  144. First endoscopic-histologic follow-up in patients with body-predominant atrophic gastritis: When should it be done?
  145. Efficacy of gluten-free diet alone on recovery from iron deficiency anemia in adult celiac patients
  146. Iron deficiency anaemia and Helicobacter pylori infection
  147. Role of Helicobacter pylori infection in pernicious anaemia
  148. Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia
  149. Long-term octreotide treatment of metastatic carcinoid tumor
  150. Duodenal Ulcer Relapse Is Not Always Associated with Recurrence of H. pylori Infection: A Prospective Three-Year Follow-Up Study
  151. Prevalence and Causes of Hypergastrinemia in Primary Hyperparathyroidism: A Prospective Study
  152. Correspondence
  153. Atrophic Body Gastritis in Patients With Autoimmune Thyroid Disease
  154. High prevalence of atrophic body gastritis in patients with unexplained microcytic and macrocytic anemia A prospective screening study
  155. Relationship between fundic endocrine cells and gastric acid secretion in hypersecretory duodenal ulcer diseases
  156. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours
  157. Omeprazole 20 or 40 mg daily for healing gastroduodenal ulcers in patients receiving non-steroidal anti-inflammatory drugs
  158. Atrophic Body Gastritis: Distinct Features Associated with Helicobacter pylori Infection
  159. Reversal of Long-Standing Iron Deficiency Anaemia after Eradication ofHelicobacter pyloriInfection
  160. Absorption of the oral iron preparation ferrous acetyl transferrin in achlorhydric patients: a pilot study
  161. Long-term intensive insulin therapy in IDDM: effects on HbA1c, risk for severe and mild hypoglycaemia, status of counterregulation and awareness of hypoglycaemia
  162. Effectiveness of octreotide in controlling fasting hypergastrinemia and related enterochromaffin-like cell growth
  163. Somatostatin Receptor Localization of Pancreatic Endocrine Tumors
  164. Modulation of Growth of Human Gastric Enterochromaffin-Like Cells
  165. Effects of Recent, Short-Term Hyperglycemia on Responses to Hypoglycemia in Humans: Relevance to the Pathogenesis of Hypoglycemia Unawareness and Hyperglycemia-Induced Insulin Resistance
  166. Erratum
  167. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM
  168. Relative roles of insulin and hypoglycaemia on induction of neuroendocrine responses to, symptoms of, and deterioration of cognitive function in hypoglycaemia in male and female humans
  169. Vasoactive intestinal polypeptide modulates the in vitro immunoglobulin a production by intestinal lamina propria lymphocytes
  170. Helicobacter pylori Infection in Children with Antral Gastrin Cell Hyperfunction
  171. Inhibitory effect of somatostatin-14 and some analogues on human natural killer cell activity
  172. Meticulous Prevention of Hypoglycemia Normalizes the Glycemic Thresholds and Magnitude of Most of Neuroendocrine Responses to, Symptoms of, and Cognitive Function During Hypoglycemia in Intensively Treated Patients With Short-Term IDDM
  173. Morphometry of gastric endocrine cells in hypergastrinemic patients treated with the somatostatin analogue octreotide
  174. Maintenance Treatment with H2 Receptor Antagonists for Duodenal Ulcer Disease: Toward a Rational Use
  175. Focal oxyntic gland atrophy with endocrine cell hyperplasia in Zollinger?Ellison syndrome during omeprazole treatment
  176. Modulation of human natural killer activity by vasoactive intestinal peptide (VIP) family. VIP, glucagon and GHRF specifically inhibit NK activity
  177. Gut neuropeptides and the immune system
  178. Effects of somatostatin on human intestinal lamina propria lymphocytes. Modulation of lymphocyte activation
  179. Neurohumoral control of gallbladder motility in healthy subjects and diabetic patients with or without autonomic neuropathy
  180. Effect of Vasoactive Intestinal Peptide Neuropeptide on Natural Killer Activity from Peripheral Blood Lymphocytes of Normal Subjects
  181. Effects of high in vivo levels of vasoactive intestinal polypeptide on function of circulating lymphocytes in humans
  182. Modulatory Effects of Somatostatin and Vasoactive Intestinal Peptide on Human Intestinal Lymphocytes
  183. Medical Treatment of Antral Gastrin Cell Hyperfunction: Role of Nonantisecretory Therapy
  184. Somatostatin Infused during Acute Pancreatitis Retains Its Biological Activity
  185. Loss of Efficacy of Famotidine in the Control of Gastric Acid Secretion in Patients with Zollinger-Ellison Syndrome Reversed by Omeprazole
  186. HYPERGASTRINAEMIA AFTER LONG-TERM H2-BLOCKER TREATMENT
  187. Pancreatic polypeptide response to a protein-rich meal in diabetic patients with and without neuropathy
  188. Gastric acid and pancreatic polypeptide responses to modified sham feeding: indication of an increased basal vagal tone in a subgroup of duodenal ulcer patients.
  189. Evidence that bombesin releases extragastric gastrin in man
  190. Bombesin effects on human GI functions
  191. Peptides of the APUD system in amphibian skins
  192. Bombesin, Trypsin, and Chronic Pancreatitis
  193. Effect of Bombesin on Plasma Insulin, Pancreatic Glucagon, and Gut Glucagon in Man*
  194. NEUROTENSIN AND THE DUMPING SYNDROME